Form D · Other

AQUINOX PHARMACEUTICALS (USA) INC

Richmond, A1 · CIK 0001404644

Offering snapshot reported Apr 1, 2013 · SEC filing

Reported sold
$14M
Offering amount: $21M
Investors reported
7
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 19, 2013
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 1, 2013Initial$13,999,975No comparison7SEC filing
Sep 26, 2011Initial$3,536,035No comparison6SEC filing
Feb 11, 2011Initial$4,724,298No comparison6SEC filing
Jun 25, 2010Initial$3,531,483No comparison1SEC filing
Apr 15, 2010Initial$4,827,549No comparison5SEC filing
Feb 28, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Jun 25, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-194308

Source: Form D, filed Apr 1, 2013. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kamran Alam Executive
Kenneth Galbraith Director
Frank Holler Director
Elaine Jones Director
Kevin Leslie Director
Daniel Levitt Director
David Main Director, Executive
Stephen Majlath Executive
Asish Xavier Director

Issuer details

Industry: Other (See others in industry)

Address:
5600 Parkwood Way, Suite 430
Richmond, A1, V6V 2M2